MyFinsight
Home
Blog
About
Contact
Download
Download image
Receivable from
collaboration partner
-$164,879K
Proceeds from issuance of
common stock upon...
$23,343K
Stock-based compensation
$45,974K
Accrued expenses and
other payables
$4,576K
Accounts payable
$3,723K
Non-cash lease expense
$1,588K
Depreciation
$1,280K
Net cash provided by
(used in) operating...
$57,671K
Net cash provided by
financing activities
$22,864K
Canceled cashflow
$164,349K
Canceled cashflow
$479K
Revenue
$46,016K
Interest income
$28,789K
Other segment items
-$27K
Net increase
(decrease) in cash, cash...
$31,203K
Canceled cashflow
$49,332K
Net (loss) income
-$130,149K
Deferred revenue
-$21,017K
Accretion of discount on
marketable securities
$7,223K
Income taxes payable
-$2,689K
Prepaid expenses and
other assets
$2,360K
Operating lease liability
$903K
Other
-$8K
Proceeds from maturities
of marketable...
$491,840K
Proceeds from sale of
marketable securities
$7,003K
Tax withholding
payments related to net...
$479K
Canceled cashflow
$74,832K
Net cash used in
investing activities
-$49,332K
Canceled cashflow
$498,843K
Development department
expense (excluding...
$65,987K
Stock-based compensation
expense
$45,974K
General and
administrative expenses...
$23,401K
Discovery department
expense (excluding...
$21,822K
Employee wages and
benefits - development
$21,392K
Employee wages and
benefits - general and...
$15,688K
Employee wages and
benefits - discovery
$9,879K
Income tax expense
$838K
Purchase of marketable
securities
$546,585K
Purchases of property and
equipment
$1,590K
Back
Back
Cash Flow
source: myfinsight.com
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)